An Open Label Multi-part First-in-human Study of Oral LMI070 in Infants With Type 1 Spinal Muscular Atrophy

Trial Profile

An Open Label Multi-part First-in-human Study of Oral LMI070 in Infants With Type 1 Spinal Muscular Atrophy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs LMI 070 (Primary)
  • Indications Spinal muscular atrophy
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Novartis
  • Most Recent Events

    • 03 Aug 2017 Planned number of patients changed from 42 to 44.
    • 24 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 30 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top